Nanotechnology Now - Press Release: "NanoViricides, Inc. Presents at the BARDA Industry Day"

Home > Press > NanoViricides, Inc. Presents at the BARDA Industry Day

Abstract:
anoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that it presented its current progress at the 2007 Biomedical Advanced Research and Development Authority (BARDA) Industry Day on Friday, August 3, which followed the HHS Public Health Emergency Medical Countermeasures (PHEMC) Enterprise Stakeholders Workshop ( http://www.hhs.gov/aspr/barda/phemce/workshop/2007/2007workshop.html ) in Washington, DC.

NanoViricides, Inc. Presents at the BARDA Industry Day

WEST HAVEN, CT | Posted on August 6th, 2007

"The strong preclinical success of our nanoviricides pandemic influenza drug candidates, FluCide-HP ™ and AviFluCide ™ has generated significant interest," reports Dr. Anil R. Diwan, President of the Company, adding further, "The broad-spectrum antivirals including FluCide-I ™ that we are developing now, as well as our novel Flexible Biosecurity 'Just-In-Time Accurate Drug' platform technology will be extremely valuable to overall national biosecurity."

Approximately fifteen companies presented in the Therapeutics section. NanoViricides, Inc. was the only nanomedicine-based antiviral therapeutics company at the Industry Day.

"Our leadership position in nanomedicine against viral diseases, and the potential to create the equivalent of penicillin-like broad-spectrum drugs against viruses is now well recognized," said Dr. Eugene Seymour, MD, MPH, CEO, NanoViricides, Inc.

BARDA is currently authorized to spend $1.07 billion on acquisition and advanced development activities from 2006 to 2008. The National Institutes of Health (NIH), and in particular, National Institute for Allergy and Infectious Diseases (NIAID), in partnership with BARDA, are generally responsible for enabling many eligible novel technologies for further development towards the goal of acquisition.

####

About NanoViricides, Inc.
NanoViricides, Inc. ( http://www.nanoviricides.com ) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward looking statements are subject to known and unknown risks, uncertainties and other factors including the availability of adequate financing, the success of the Company's research and development strategy, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission. Such risks, uncertainties and other factors may cause actual results, performance, or achievements of the Company to be different from those expressed or implied by the Company.

For more information, please click here

Contacts:
NanoViricides, Inc.
Amanda Schuon, 310-550-7200

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: